41
Safety Study of Alphanate in Previously Treated Patients With Severe Hemophilia A
Condition(s):Severe Hemophilia ALast Updated:February 5, 2020Unknown status
Factor VIII: 838 Clinical Trials, Page 5 of 84
Hide Studies Not Open or Pending
42
A Safety, Tolerability, and Pharmacokinetics Study of a Single Intravenous Injection of Recombinant Coagulation Factor VIII Fc – Von Willebrand Factor – XTEN Fusion Protein (rFVIIIFc-VWF-XTEN) (BIVV001) in Previously Treated Adults With Severe Hemophilia A (EXTEN-A)
Condition(s):Hemophilia ALast Updated:April 19, 2022Completed
43
A Post Marketing Surveillance Study for ADYNOVATE in South Korea
Condition(s):Hemophilia ALast Updated:December 28, 2021Recruiting
44
Study to Test the Safety and How Well Patients With Severe Hemophilia A Respond to Treatment With BAY 2599023 (DTX 201), a Drug Therapy That Delivers a Healthy Version of the Defective Factor VIII Gene Into the Nucleus of Liver Cells Using an Altered, Non-infectious Virus (AAV) as a “Shuttle”.
Condition(s):Hemophilia ALast Updated:May 2, 2022Recruiting
45
Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients
Condition(s):Hemophilia ALast Updated:May 24, 2021Completed
46
China ADVATE PTP Study
Condition(s):Hemophilia ALast Updated:May 3, 2021Completed
47
A Study to Compare the Pharmacokinetics and Safety of Current Factor VIII Concentrate and Optivate® in Haemophilia A.
Condition(s):Von Willebrand DiseaseLast Updated:February 15, 2018Completed
48
Evaluation of Long-term Safety of ADYNOVI/ADYNOVATE (Antihaemophilic Factor [Recombinant] PEGylated, Rurioctocog Alfa Pegol) in Patients With Haemophilia A – An ADYNOVI/ADYNOVATE Post-Authorisation Safety Study (PASS)
Condition(s):Hemophilia ALast Updated:September 1, 2021Recruiting
49
Prospective and Retrospective, Non-interventional Study to Evaluate the Safety and Effectiveness of Obizur in Real-life Practice
Condition(s):Acquired Hemophilia ALast Updated:September 22, 2021Completed
50
A Trial Investigating Safety and Efficacy of Treatment With BAY94-9027 in Severe Hemophilia A
Condition(s):Hemophilia ALast Updated:December 2, 2020Completed